Elekta (OTCMKTS:EKTAY) Sees Unusually-High Trading Volume – Here’s Why

Elekta AB (OTCMKTS:EKTAY) saw unusually-strong trading volume on Wednesday . Approximately 1,069 shares were traded during trading, an increase of 328% from the previous session’s volume of 250 shares.The stock last traded at $6.27 and had previously closed at $6.15.

Analysts Set New Price Targets

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Elekta Stock Up 3.0%

The firm’s 50-day moving average price is $5.47 and its two-hundred day moving average price is $5.19. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.79 and a current ratio of 1.04. The firm has a market cap of $2.31 billion, a PE ratio of 89.66 and a beta of 1.04.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings results on Wednesday, November 26th. The company reported $0.07 EPS for the quarter. The firm had revenue of $427.85 million for the quarter, compared to analyst estimates of $436.91 million. Elekta had a net margin of 1.62% and a return on equity of 12.14%. As a group, equities research analysts expect that Elekta AB will post 0.36 EPS for the current fiscal year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.